Literature DB >> 30948110

Lipoamino acid-based cerasomes for doxorubicin delivery: Preparation and in vitro evaluation.

A Gileva1, G Sarychev2, U Kondrya2, M Mironova2, A Sapach3, O Selina3, U Budanova2, S Burov4, Yu Sebyakin2, E Markvicheva3.   

Abstract

Cerasomes are hybrid organic-inorganic nanoparticles (NPs) that could be considered as liposomes with rather durable silicon shell. In this study, several cerasome-forming lipoamino acids (CFLA) were synthesized and used as structural blocks for cerasome preparation. Pure cerasomes which contained only CFLA, and mixed cerasomes based on a mixture of CFLA with a disintegrating dipalmitoylphosphatidylcholine (DPPC) lipid were fabricated and characterized in terms of morphology, mean size, ζ-potential, stability at storage. All obtained cerasome samples were found to be much more stable at storage than conventional liposomes (120 and 10 days, respectively). The cerasomes were loaded with doxorubicin (DOX) and tested in vitro using human breast adenocarcinoma MCF-7. Effects of the lipid composition on the physical-chemical properties and cellular uptake of the cerasomes both in 2D (monolayer culture) and 3D (multicellular tumor spheroids) were studied. The biggest accumulation efficiencies as well as the highest cytotoxicity level were found for the mixed cationic cerasomes. These cerasomes could be proposed as promising drug delivery system for cancer treatment.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  3D in vitro model; Cerasomes; Cytotoxicity; Doxorubicin; MCF-7 cells; Multicellular tumor spheroids; Organic-inorganic nanoparticles; Passive targeting; Sustained drug release

Mesh:

Substances:

Year:  2019        PMID: 30948110     DOI: 10.1016/j.msec.2019.02.111

Source DB:  PubMed          Journal:  Mater Sci Eng C Mater Biol Appl        ISSN: 0928-4931            Impact factor:   7.328


  1 in total

1.  Preparation, evaluation and metabolites study in rats of novel amentoflavone-loaded TPGS/soluplus mixed nanomicelles.

Authors:  Xue Feng; Yuting Chen; Luya Li; Yuqian Zhang; Lantong Zhang; Zhiqing Zhang
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.